Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer

Cancer Communications

article

Dingxie Liu¹  Yong Wu² 

[1] Bluewater Biotech LLC;Division of Cancer Research and Training, Department of Internal Medicine, Charles R. Drew University of Medicine and Science;David Geffen UCLA School of Medicine, and UCLA Jonsson Comprehensive Cancer Center

关键词: Anaplastic Lymphoma Kinase;    Breast cancer;    Differentiation;    Disease free survival;    Gene signature;    Neoadjuvant chemotherapy response;    Prognosis prediction;   

DOI  :  10.1002/cac2.12038

学科分类：社会科学、人文和艺术（综合）

来源: Springer

【 摘 要 】

Background Aberrant activation of anaplastic lymphoma kinase (ALK) signaling has been found to be involved in the tumorigenesis of multiple types of cancer. The aim of this study was to determine the role of this pathway in the pathogenesis of breast cancer. Methods An ALK pathway signature that we generated previously was used to compute the ALK pathway activity in 6381 breast cancer samples from 42 microarray datasets, and the associations between ALK pathway signature score and clinical variables were examined using logistic regression and survival analyses. Results Our results indicated that high ALK pathway activity was a significant risk factor for hormone receptor-negative, high-grade breast cancer in the 42 datasets. ALK pathway activity was positively associated with pathological complete response (pCR) in 15 datasets annotated with patient's neoadjuvant chemotherapy response information (overall odds ratio = 1.67, P   50 years old, with positive lymph nodes, or with residual disease after neoadjuvant chemotherapy. Conclusions ALK may be involved in breast cancer tumorigenesis, and ALK pathway signature score may serve as a prognostic biomarker for breast cancer.

【 授权许可】

CC BY|CC BY-NC-ND